



# Avior Bio Announces Positive Results with AV104 Buccal Film in First-in-Human Phase 1 Study

October 20, 2020

HOLLY SPRINGS, NC - Avior Bio is pleased to announce the results of its first clinical trial with AV104 buccal film. AV104 buccal film is an experimental drug product under development for the treatment of pruritus associated with chronic liver disease and other conditions.

Twelve normal healthy volunteers participated in the single-dose, crossover, safety, tolerability, and pharmacokinetic study with AV104 buccal film and a tablet product. The drug absorption from the AV104 buccal film was higher than with the tablet and treatment emergent adverse events were similar with the two products.

“With the drug pharmacokinetic profile from AV104 buccal film, and no tolerability concerns, we can proceed with our development plans including initiation of Phase 2 studies to assess the efficacy and safety of the product in patients with chronic liver disease,” said Dr. Andrew Finn, Chief Medical Officer.

“We are excited about our results. We also have excellent feedback from the FDA on our program. We look forward to building Avior as we strive to be first-to-market for patients suffering from pruritus in liver disease.” added Dr. Niraj Vasisht, President and CEO.

Avior Bio is currently preparing itself to raise its Series A round of \$7.5 million for the completion of Phase IIA clinical program for the treatment of pruritus in both liver disease and atopic dermatitis by 1H2022.

## **About Pruritus**

Intermittent moderate-to-severe-pruritus (itch) is a common comorbid symptom of chronic liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic liver disease (ALD), fatty liver disease (FLD), hepatitis (B/C), and liver cirrhosis. It is estimated

that over 2.5 million patients suffer from persistent pruritus in liver disease patients with no FDA approved therapies currently available. Pruritus in liver disease reduces the patients' quality of life (QOL) causing insomnia, anxiety, depression, nocturnal scratching, excoriation, and bleeding. The disease state is also common in atopic dermatitis (*eczema*) where 15.6 million patients experience pruritus. Avior plan to study AV104 buccal film for treatment of pruritus in Atopic dermatitis as well.

### **About Avior Bio**

Avior Bio Inc. is a clinical-stage, pharmaceutical company dedicated to the treatment of pruritus in liver disease and atopic dermatitis. Our lead product – AV104 buccal film- focuses on the treatment for moderate to severe pruritus in patients suffering from liver disease. AV104 buccal film is designed to avoid the first-pass metabolism of the impaired liver. Avior is seeking approval of AV104 buccal film through an NDA submission in 2H2023. For further information about Avior Bio Inc. visit their website at [www.aviorbio.com](http://www.aviorbio.com)